"The AAN and ANA recognize there are differing ethical opinions on the status of embryos that cannot be resolved to the satisfaction of all through medical science alone," according to American Academy of Neurology president Sandra F. Olson, MD. "Nevertheless, as scientists and healers, we have a strong moral and ethical obligation to pursue research that may result in beneficial treatments for diseases that are among the most debilitating and costly in human society," said Olson.
"Our organizations therefore recommend that embryonic stem cell research and somatic cell nuclear transfer (i.e., therapeutic cloning) proceed under federal oversight, ensuring that the highest quality and most promising research is conducted with utmost regard for ethical standards," said Olson.
Neuroscientists agree that there is great potential, although no guarantees, for breakthroughs in therapies for diseases such as ALS (amyotrophic lateral sclerosis), Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, spinal cord injury, and stroke, through embryonic stem cell research.
While adult stem cell research is believed to hold less promise, the AAN and ANA believe both embryonic and adult stem cell research should be pursued rigorously and under close scrutiny. The organizations further endorsed the standards for oversight developed by the National Institutes of Health in its 2000 report, "Guidelines for Research Involving Human Pluripotent Stem Cells." Those guidelines were altered in August 2001 by Presidential Order and limited the research to stem cell lines that had already been derived at that time. Many researchers believe that these lines are inadequat
'"/>
Contact: Kathy Stone
kstone@aan.com
651-695-2789
American Academy of Neurology
26-Oct-2004